[1] = http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInfo...
[2] = http://www.slate.com/articles/health_and_science/medical_exa...
[3] = http://www.thelancet.com/journals/lancet/article/PIIS0140-67...
[4] = http://www.consumersunion.org/pub/core_health_care/001651.ht...
The article cites many university studies which show that use of SSRIs actually coincided with a decreased risk of suicidal ideation.
Is there more recent evidence to suggest the British studies were correct?
I hear a lot of anecdotal evidence when SSRIs and other anti-depressants are discussed, which I agree is important because everyone can react differently to them and doctors and patients should be aware of what may occur, but the article you linked to actually states that the clinical evidence is in support of SSRI prescription in all age groups with major depression.
EDIT: I do note that the article mentions the GSK settlement with Spitzer, and regardless of whether the studies hold true, they should not have been covered up unless there was a question to the scientific standards of the trials.
A very large part of the multi-billion dollar a year R&D budgets of the pharmaceutical companies go to pay for clinical trials. How would you replace that money?
Having a vested interest control scientific studies is poor regulatory system design.
Also, drug companies often hire physicians and researchers (often the best ones) to help with drug development far before any trial is run. Would you like to exclude those experts from input on the trial design?
From your comment I get the sense you have a limited understanding of what is really involved in drug development.
However you appear to have retired undefeated as devil's advocate, as if the questions you put are unanswerable.
I would admit that there are more questions and answers that need to be given before we fully implement my HN comment, but that is hardly a refutation of the core idea: that a system free of conflict-of-interest requires independent entities and umpires that are more empowered than the conflicted interests in that system.
A recent Forbes opinion piece has its own take on inserting independent entities into the system [0]:
What we need is a construct with teeth, an established network of industry-independent researchers (not contractors) equipped to evaluate trial design, statistical power, data analysis, and interpretation, not as regulators but as contributors to final research publications. It would be a sort of Congressional Budget Office for clinical trial results.
Admittedly the position outlined in that article does not go as far as a completely independent entity operating all clinical trials for the purposes of regulatory approval, but it's in the right direction.
[0] http://www.forbes.com/sites/emilywillingham/2012/11/26/how-c...
For example, Pfizer was found guilty of promoting Bextra off label, a very serious charge from the viewpoint of the FDA and the Justice Department. Punishment includes banning companies from doing business with CMS (who run Medicare and Medicaid).
Pfizer entered into an agreement with the Justice Department/HHS where a shell company was allowed to plead guilty and be banned from doing business with Medicare. That's right, a shell company that doesn't actually sell any drugs.
http://www.cnn.com/2010/HEALTH/04/02/pfizer.bextra/index.htm...
I'd agree the unwillingness of the gov't to use the powers it has is a problem. But that's a separate and equally important issue that others in this thread have flagged, filed under the label 'regulatory capture'.
It's not a situation that requires fire and brimstone and outrage. It should just be approached with dispassionate understanding: we have a defective system that is not designed to withstand attacks by self-interested system 'hackers'.
The solution is to design a system that neutralises short-term, narrow self-interest.
Publishing every single trial will probably also make more expensive.
That's what you get when you end up with an overly-regulated market for drugs. You cannot publish anything about them without governmental authorization.
I agree with the premise of the petition but a petition is a very weak tool to reach that goal. It will get you nowhere.
I fail to see where there is "under-regulation" in the pharma industry. Try setting up a Pharma business, you will be surprised how hard it has become.
Signed and donated.
This is a great effort, and I suggest others help out as well. The amount of fake trials and hidden experiment data that pharmas participate in is absurd. I can't recall the exact incident ('carbocation probably will) but within the last decade there was a rather large scandal where a particular drug was known to have a fatal side effect -- suicidal ideation, I believe [wrong, valvular heart damage - see below] -- and more than 90% of the trial data that pointed to said effect was hidden and concealed. The drug hit the market and was later pulled off the shelves because, you guessed it, people started dying! While I don't believe the reporting of all trials will fix that level of deceit, it's certainly a great step in the right direction. Pushing for public reporting of data concerning meds that people might eventually put into their bodies only makes sense.
Next up: Abolishing sponsored research clinical trials, or at least increasing the transparency of research sponsorship instead of burying the fact that the research PI is actually an employee of Pfizer somewhere deep in the appendices.
It's amazing how we have organizations like Consumer Reports to give us objective reviews of toasters and cars, yet nothing like that exists for medications or medical devices, isn't it?
Edit: So I'm confusing 2 things:
1) Fen-phen was a diet pill pushed to market despite evidence that it caused valvular heart damage. It was pulled from the market. Read: http://www.pbs.org/wgbh/pages/frontline/shows/prescription/h...
2) SSRIs were the drugs that increase suicidality (something commonly known now) and the data confirming that was reportedly hidden by pharmas. Read: http://reason.com/archives/2007/07/10/can-caution-be-too-ris...